These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 29498789)

  • 21. Palbociclib, a selective CDK4/6 inhibitor, enhances the effect of selumetinib in RAS-driven non-small cell lung cancer.
    Zhou J; Zhang S; Chen X; Zheng X; Yao Y; Lu G; Zhou J
    Cancer Lett; 2017 Nov; 408():130-137. PubMed ID: 28866094
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting the PI3K signaling pathway in KRAS mutant colon cancer.
    Hong S; Kim S; Kim HY; Kang M; Jang HH; Lee WS
    Cancer Med; 2016 Feb; 5(2):248-55. PubMed ID: 26715098
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synergistic anticancer efficacy of MEK inhibition and dual PI3K/mTOR inhibition in castration-resistant prostate cancer.
    Park H; Kim Y; Sul JW; Jeong IG; Yi HJ; Ahn JB; Kang JS; Yun J; Hwang JJ; Kim CS
    Prostate; 2015 Nov; 75(15):1747-59. PubMed ID: 26250606
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthetic miR-143 Inhibits Growth of HER2-Positive Gastric Cancer Cells by Suppressing KRAS Networks Including DDX6 RNA Helicase.
    Tokumaru Y; Tajirika T; Sugito N; Kuranaga Y; Shinohara H; Tsujino T; Matsuhashi N; Futamura M; Akao Y; Yoshida K
    Int J Mol Sci; 2019 Apr; 20(7):. PubMed ID: 30959742
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of forced expression of mutated K-RAS gene on gastrointestinal cancer cell lines and the IGF-1R targeting therapy.
    Matsunaga Y; Adachi Y; Sasaki Y; Koide H; Motoya M; Nosho K; Takagi H; Yamamoto H; Sasaki S; Arimura Y; Tokino T; Carbone DP; Imai K; Shinomura Y
    Mol Carcinog; 2017 Feb; 56(2):515-526. PubMed ID: 27312358
    [TBL] [Abstract][Full Text] [Related]  

  • 26. KRAS-mutant colon cancer cells respond to combined treatment of ABT263 and axitinib.
    Wang G; Huang Y; Wu Z; Zhao C; Cong H; Ju S; Wang X
    Biosci Rep; 2019 Mar; 39(3):. PubMed ID: 30674639
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Ras destabilizer KYA1797K overcomes the resistance of EGFR tyrosine kinase inhibitor in KRAS-mutated non-small cell lung cancer.
    Park J; Cho YH; Shin WJ; Lee SK; Lee J; Kim T; Cha PH; Yang JS; Cho J; Min DS; Han G; Lee HY; Choi KY
    Sci Rep; 2019 Jan; 9(1):648. PubMed ID: 30679620
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A benzoxazole compound as a novel MEK inhibitor for the treatment of RAS/RAF mutant cancer.
    Cheng Y; Wang X; Xia X; Zhang W; Tian H
    Int J Cancer; 2019 Jul; 145(2):586-596. PubMed ID: 30628057
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of Cellular Genetic Make-up on Colorectal Cancer Cell Lines Response to Ellagic Acid: Implications of Small Interfering RNA.
    Yousef AI; El-Masry OS; Abdel Mohsen MA
    Asian Pac J Cancer Prev; 2016; 17(2):743-8. PubMed ID: 26925673
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells.
    Qin B; Ariyama H; Baba E; Tanaka R; Kusaba H; Harada M; Nakano S
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):577-84. PubMed ID: 16532343
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The comparison between dual inhibition of mTOR with MAPK and PI3K signaling pathways in KRAS mutant NSCLC cell lines.
    Dogan Turacli I; Ozkan AC; Ekmekci A
    Tumour Biol; 2015 Dec; 36(12):9339-45. PubMed ID: 26108998
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MicroRNA-425-5p Expression Affects BRAF/RAS/MAPK Pathways In Colorectal Cancers.
    Angius A; Pira G; Scanu AM; Uva P; Sotgiu G; Saderi L; Manca A; Serra C; Uleri E; Piu C; Caocci M; Ibba G; Zinellu A; Cesaraccio MR; Sanges F; Muroni MR; Dolei A; Cossu-Rocca P; De Miglio MR
    Int J Med Sci; 2019; 16(11):1480-1491. PubMed ID: 31673240
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
    Guenther MK; Graab U; Fulda S
    Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression.
    Jin H; Jang Y; Cheng N; Li Q; Cui PF; Zhou ZW; Jiang HL; Cho MH; Westover KD; Tan QY; Xu CX
    J Exp Clin Cancer Res; 2019 Apr; 38(1):165. PubMed ID: 30987652
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer.
    Ku BM; Jho EH; Bae YH; Sun JM; Ahn JS; Park K; Ahn MJ
    Invest New Drugs; 2015 Feb; 33(1):12-21. PubMed ID: 25342139
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer.
    Bao R; Lai CJ; Wang DG; Qu H; Yin L; Zifcak B; Tao X; Wang J; Atoyan R; Samson M; Forrester J; Xu GX; DellaRocca S; Borek M; Zhai HX; Cai X; Qian C
    Mol Cancer Ther; 2009 Dec; 8(12):3296-306. PubMed ID: 19952121
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of MIR143 on rat sarcoma signaling networks in solid tumors: A brief overview.
    Tokumaru Y; Takabe K; Yoshida K; Akao Y
    Cancer Sci; 2020 Apr; 111(4):1076-1083. PubMed ID: 32077199
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibody-mediated delivery of anti-KRAS-siRNA in vivo overcomes therapy resistance in colon cancer.
    Bäumer S; Bäumer N; Appel N; Terheyden L; Fremerey J; Schelhaas S; Wardelmann E; Buchholz F; Berdel WE; Müller-Tidow C
    Clin Cancer Res; 2015 Mar; 21(6):1383-94. PubMed ID: 25589625
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel β-phenylacrylic acid derivatives exert anti-cancer activity by inducing Src-mediated apoptosis in wild-type KRAS colon cancer.
    Kim SJ; Noh TH; Son S; Kim DH; Kim W; Lee Y; Choo J; Heo G; Kim MJ; Chung HY; Jung Y; Jung JH; Moon HR; Im E
    Cell Death Dis; 2018 Aug; 9(9):877. PubMed ID: 30158525
    [TBL] [Abstract][Full Text] [Related]  

  • 40. miR-19b enhances proliferation and apoptosis resistance via the EGFR signaling pathway by targeting PP2A and BIM in non-small cell lung cancer.
    Baumgartner U; Berger F; Hashemi Gheinani A; Burgener SS; Monastyrskaya K; Vassella E
    Mol Cancer; 2018 Feb; 17(1):44. PubMed ID: 29455644
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.